Abstract
In countries with social health-care systems, pricing and market access barriers represent perhaps the biggest challenge to pharmaceutical and medical device companies trying to commercialise new products. It is important for both health system managers and manufacturers to be clear about which product attributes these complex ‘reward frameworks'are trying to incentivise. This transparency will allow pricing and market access systems to be closer aligned with broader health policy goals, and give manufacturers clear guidance on the types of products society wishes them to deliver. This article seeks to deconstruct the pricing and market access frameworks for five European countries and identify the product attributes and manufacturer behaviours that are implicitly being rewarded.
Get full access to this article
View all access options for this article.